- Home
- EVAX vs PMN Comparison
EVAX vs PMN Comparison
Compare EVAX & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- PMN
- Stock Information
- Founded
- EVAX 2008
- PMN 2004
- Country
- EVAX Denmark
- PMN Canada
- Employees
- EVAX N/A
- PMN N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- PMN Pharmaceuticals and Biotechnology
- Sector
- EVAX Health Care
- PMN Health Care
- Exchange
- EVAX Nasdaq
- PMN Nasdaq
- Market Cap
- EVAX 16.3M
- PMN 18.8M
- IPO Year
- EVAX 2021
- PMN N/A
- Fundamental
- Price
- EVAX $1.49
- PMN $0.59
- Analyst Decision
- EVAX Strong Buy
- PMN Strong Buy
- Analyst Count
- EVAX 2
- PMN 1
- Target Price
- EVAX $10.00
- PMN $6.00
- AVG Volume (30 Days)
- EVAX 76.2K
- PMN 37.4K
- Earning Date
- EVAX 05-27-2025
- PMN 05-13-2025
- Dividend Yield
- EVAX N/A
- PMN N/A
- EPS Growth
- EVAX N/A
- PMN N/A
- EPS
- EVAX N/A
- PMN 0.11
- Revenue
- EVAX $3,344,000.00
- PMN N/A
- Revenue This Year
- EVAX $102.45
- PMN N/A
- Revenue Next Year
- EVAX $100.30
- PMN N/A
- P/E Ratio
- EVAX N/A
- PMN $5.68
- Revenue Growth
- EVAX 4480.82
- PMN N/A
- 52 Week Low
- EVAX $1.20
- PMN $0.51
- 52 Week High
- EVAX $21.80
- PMN $2.37
- Technical
- Relative Strength Index (RSI)
- EVAX 43.19
- PMN 43.65
- Support Level
- EVAX $1.20
- PMN $0.51
- Resistance Level
- EVAX $1.46
- PMN $0.65
- Average True Range (ATR)
- EVAX 0.13
- PMN 0.09
- MACD
- EVAX 0.03
- PMN 0.01
- Stochastic Oscillator
- EVAX 59.18
- PMN 32.58
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.